1. Home
  2. IMCR vs PFS Comparison

IMCR vs PFS Comparison

Compare IMCR & PFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IMCR
  • PFS
  • Stock Information
  • Founded
  • IMCR 2008
  • PFS 1839
  • Country
  • IMCR United Kingdom
  • PFS United States
  • Employees
  • IMCR N/A
  • PFS N/A
  • Industry
  • IMCR Biotechnology: Biological Products (No Diagnostic Substances)
  • PFS Savings Institutions
  • Sector
  • IMCR Health Care
  • PFS Finance
  • Exchange
  • IMCR Nasdaq
  • PFS Nasdaq
  • Market Cap
  • IMCR 1.5B
  • PFS 2.2B
  • IPO Year
  • IMCR 2021
  • PFS N/A
  • Fundamental
  • Price
  • IMCR $32.75
  • PFS $18.53
  • Analyst Decision
  • IMCR Buy
  • PFS Strong Buy
  • Analyst Count
  • IMCR 10
  • PFS 5
  • Target Price
  • IMCR $58.13
  • PFS $23.60
  • AVG Volume (30 Days)
  • IMCR 439.6K
  • PFS 702.4K
  • Earning Date
  • IMCR 08-07-2025
  • PFS 07-24-2025
  • Dividend Yield
  • IMCR N/A
  • PFS 5.18%
  • EPS Growth
  • IMCR N/A
  • PFS N/A
  • EPS
  • IMCR N/A
  • PFS 1.19
  • Revenue
  • IMCR $333,581,000.00
  • PFS $700,486,000.00
  • Revenue This Year
  • IMCR $26.82
  • PFS $26.03
  • Revenue Next Year
  • IMCR $8.15
  • PFS $7.82
  • P/E Ratio
  • IMCR N/A
  • PFS $15.61
  • Revenue Growth
  • IMCR 25.75
  • PFS 58.68
  • 52 Week Low
  • IMCR $23.15
  • PFS $14.16
  • 52 Week High
  • IMCR $41.54
  • PFS $22.24
  • Technical
  • Relative Strength Index (RSI)
  • IMCR 49.96
  • PFS 67.98
  • Support Level
  • IMCR $30.76
  • PFS $17.40
  • Resistance Level
  • IMCR $32.55
  • PFS $18.00
  • Average True Range (ATR)
  • IMCR 1.49
  • PFS 0.45
  • MACD
  • IMCR -0.25
  • PFS 0.20
  • Stochastic Oscillator
  • IMCR 32.68
  • PFS 98.67

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About PFS Provident Financial Services Inc

Provident Financial Services Inc is the holding company for The Provident Bank, a community-oriented bank. The Company's operations are solely in the financial services industry and include providing traditional banking and other financial services to its customers. The Company operates in the geographical regions of northern and central New Jersey, Queens and Nassau Counties in New York and eastern Pennsylvania. The Company has a single reporting segment for financial reporting purposes. The majority of the revenue-generating activities that are components of non-interest income are These revenue streams can generally be classified into three broad categories: wealth management revenue, insurance agency income, and banking service charges and other fees.

Share on Social Networks: